Guanzi Pharmaceutical

Guanzi Pharmaceutical (Guanzi (Beijing) Pharmaceutical Technology) is a clinical-stage biopharmaceutical company focused on the development of innovative small molecule therapeutics for autoimmune and inflammatory diseases. Founded in 2021 by industry veteran Dr. Jinsong Ni, who previously led inflammation and retinal R&D at Allergan and AbbVie, the company targets validated pathways such as TYK2 and JAK with high selectivity. Its lead candidate, GZ101, is a potent TYK2 inhibitor currently undergoing Phase 2 clinical trials for plaque psoriasis, aiming for a best-in-class safety and efficacy profile. The company's pipeline also includes dual inhibitors and other candidates designed to treat immune-mediated conditions like atopic dermatitis and lupus. Guanzi is headquartered in Beijing and maintains a focus on high-selectivity medicinal chemistry and translational research.